Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Share News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 370.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 20.00 (5.556%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 370.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MaxCyte expecting strong 2023 after decent results

Thu, 16th Mar 2023 15:01

(Sharecast News) - Cell engineering specialist MaxCyte reported total revenue of $12.4m in the fourth quarter of 2022 on Thursday, making for an increase of 22% year-on-year.

The AIM-traded company said full-year revenue for 2022 was $44.3m, representing growth of 31% compared to 2021.

It said its core business revenue increased 4% in the fourth quarter, led by a 4% increase in revenue from cell therapy customers and a 5% increase in revenue from drug discovery clients.

For the full year, core business revenues grew 26%, with cell therapy revenue up 33% and drug discovery revenue ahead 8%.

Looking ahead, MaxCyte said it was expecting total revenue growth of 21% to 26% over 2022 this year, including core revenue growth of 20% to 25%.

Additionally, it said it expected strategic platform licence (SPL) programme-related revenue of about $6m.

The firm reported total cash, cash equivalents, and short-term investments of $227.3m at year-end on 31 December.

"We are pleased with our strong progress and performance in 2022 and look forward to continuing this positive momentum into 2023," said president and chief executive officer Doug Doerfler.

"Over the course of the year, we have made significant investments in our people, manufacturing capacity, and research and development infrastructure, which positions us well for our next stage of growth.

"Our portfolio of partnerships continued to grow throughout 2022, having announced three new SPL partnerships as well as the recent addition of Catamaran Bio as a partner in early 2023."

Doerfler noted that MaxCyte also entered into a partnership with Vertex following the transfer of the exa-cel program from CRISPR.

"The partnership maintains our role in this program, for which Vertex is currently seeking regulatory marketing approval in the United States and Europe for sickle cell disease and beta-thalassemia.

"We are continuing to see our partners make strong progress across their clinical programs and are focused on providing them with the in-house manufacturing and regulatory support that they will require as they move towards commercialization.

"Our partnership pipeline remains robust and growing as we begin 2023 and we are excited to see our partners achieve upcoming milestones and move the cell therapy industry forward."

At 1442 GMT, shares in MaxCyte were flat at 1442 GMT.

Reporting by Josh White for Sharecast.com.

More News
8 May 2019 15:58

MaxCyte begins dosing second cohort in MCY-M11 clinical trial

(Sharecast News) - Clinical-stage, cell-based therapies and life sciences company MaxCyte has initiated dosing for the second cohort of patients in its US phase 1 clinical trial with MCY-M11 - the lead, wholly-owned, non-viral mRNA-based cell therapy candidate from its CARMA platform - it announced on Wednesday.

Read more
8 May 2019 12:11

MaxCyte Dosing Second Patients Group In Phase One Cancer Drug Trial

LONDON (Alliance News) - MaxCyte Inc on Wednesday said it has begun dosing for the second cohort of patients in its phase one trial of cancer drug MCY-M11.Shares in MaxCyte were down 5.7% a

Read more
24 Apr 2019 11:37

MaxCyte Outlook Confident As Loss Narrows In 2018 On Higher Revenue

LONDON (Alliance News) - MaxCyte Inc on Wednesday said its loss narrowed in 2018 on higher annual fees from its partners as it progresses on MCY-M11 therapeutic candidate development.The a

Read more
17 Apr 2019 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

Thursday 18 April UnileverQ1 ResultsPZ CussonsTrading SolutionsTrading 19 events

Read more
8 Apr 2019 13:58

MaxCyte Launches ExPERT Cellular Engineering Technology Platform

LONDON (Alliance News) - MaxCyte Inc on Monday announced the launch of its new ExPERT technology platform for use in cellular engineering.MaxCyte also noted that its business had produced

Read more
8 Apr 2019 08:34

MaxCyte launches new generation of cellular engineering instruments

(Sharecast News) - MaxCyte on Monday launched its ExPERT technology platform, a family of instruments that are the next generation of its complex cellular engineering technology.

Read more
1 Mar 2019 10:05

MaxCyte Inks Multi-Drug Clinical And Commercial Agreement With Kite

LONDON (Alliance News) - Biotechnology company MaxCyte Inc on Friday said it has expanded its business relationship with Kite by signing a multi-drug clinical and commercial agreement.Under

Read more
5 Feb 2019 17:45

UPDATE: MaxCyte Placing Fully Subscribed; Raises Over GBP10.0 Million (ALLISS)

LONDON (Alliance News) - MaxCyte Inc on Tuesday said it has raised GBP10.0 million from a placing of 5.9 million shares at 170 pence each.The life sciences company placed 5.9 million just

Read more
5 Feb 2019 10:22

MaxCyte To Raise At Least GBP10 Million For Future Growth Plans (ALLISS)

LONDON (Alliance News) - MaxCyte Inc on Tuesday said it plans to raise at least GBP10 million via a placing of shares in order to accelerate its growth strategy.The life sciences company no

Read more
15 Jan 2019 11:18

MaxCyte Guides For Revenue Growth And Earnings Above Expectations

LONDON (Alliance News) - MaxCyte Inc on Tuesday guided for a 19% increase in its 2018 revenue with the firm expecting its annual earnings to exceed market views.The life science company in

Read more
24 Oct 2018 16:07

UK Shareholder Meetings Calendar - Next 7 Days

Thursday 25 OctoberGreen & Smart WoodsAlumasc GroupFriday 26 OctoberArgos Capital

Read more
10 Oct 2018 11:47

MaxCyte Begins Patient Trial Of Proposed Cancer Treatment MCY-M11

LONDON (Alliance News) - Life sciences and medicines company MaxCyte Inc on Wednesday said it has dosed the first patient in its phase I trial for MCY-M11.MCY-M11 is a mesothelin targeting

Read more
24 Sep 2018 10:18

MaxCyte Interim Revenue Rises But Loss Widens On CARMA Development

LONDON (Alliance News) - MaxCyte Inc on Monday said its loss widened in the first half of 2018 as it continued to invest in the development of its CARMA drug platform.The life sciences said

Read more
17 Sep 2018 16:09

UK Earnings, Trading Statements Calendar - Next 7 Days

Tuesday 18 September Ocado GroupTrading Statement DP PolandHalf Year Year Year Year

Read more
26 Jul 2018 17:50

DIRECTOR DEALINGS: Wife Of MaxCyte Non-Executive Director Buys Shares

LONDON (Alliance News) - Medical & technology company MaxCyte Inc said that Karin Johnston, wife of Non-Executive Director John Johnston, purchased 11,500 shares at a price of 240 pence per on

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.